Fidelity Management & Research Co. recently announced the acquisition of new stake in G1 Therapeutics Inc. (NASDAQ:GTHX). The institutional investor has increased its shareholding in the Healthcare company by 0.16% to 5.65 million shares with purchase of 9103.0 shares. This fresh investment now brings its stake to 14.96% valued currently at $136.98 million. In addition, The Vanguard Group, Inc. raised its holdings by 13586.0 to 1.98 million shares. And JPMorgan Investment Management, I. has lifted its position by 2.99% or 27367.0 shares – to 0.94 million shares.
With over 0.24 million G1 Therapeutics Inc. (GTHX) shares trading Friday and a closing price of $17.99 on the day, the dollar volume was approximately $4.34 million. The shares have shown a negative weekly performance of -8.12% and its price on 07/24/20 gained nearly 2.57%. Currently, there are 37.66M common shares owned by the public and among those 33.71M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 8 analysts who have offered their price forecasts for GTHX have a consensus price objective of $57.29. The analysts have set the share’s price value over the next 12 months at a high of $82.00 and a low of $23.00 should the stock experience a downside. Incidentally, analysts’ outlook for the G1 Therapeutics Inc. stock is 1.60 for the next 12 months. But an upside of 78.06% will see the stock hit the forecast high price target while mean target price for the stock is $55.00.
Insiders at the company have transacted a total of 6 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 6 of these insider trades were purchases, accounting for 19,500 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in G1 Therapeutics Inc. are Fidelity Select Port. – Health Ca, JPMorgan Small Cap Growth Fund, and Vanguard Total Stock Market Index. Fidelity Select Port. – Health Ca owns 0.93 million shares of the company’s stock, all valued at over $22.48 million. JPMorgan Small Cap Growth Fund bought 63226.0 shares to see its total holdings expand to 0.9 million shares valued at over $21.95 million and representing 2.40% of the shares outstanding. Vanguard Total Stock Market Index sold 85.0 shares to bring its total holdings to over 0.8 million shares at a value of $19.36 million. Vanguard Total Stock Market Index now owns shares totaling to 2.12% of the shares outstanding.
Shares of G1 Therapeutics Inc. (NASDAQ: GTHX) opened at $18.11, up $0.57 from a prior closing price of $17.54. However, the script later closed the day at $17.99, up 2.57%. The company’s stock has a 5-day price change of -8.12% and 31.68% over the past three months. GTHX shares are trading -33.64% year to date (YTD), with the 12-month market performance down to -29.95% lower. It has a 12-month low price of $8.80 and touched a high of $41.80 over the same period. Currently, 0.24 million shares have been traded, compared to an average intraday trading volume of 559.52K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -12.83%, -9.33%, and -7.73% respectively.
Institutional ownership of G1 Therapeutics Inc. (NASDAQ: GTHX) shares accounts for 93.50% of the company’s 37.66M shares outstanding. Mutual fund holders own 34.61%, while other institutional holders and individual stakeholders account for 47.50% and 29.76% respectively.
It has a market capitalization of $689.50M. The earnings-per-share (ttm) stands at -$3.45. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.24% over the week and 6.56% over the month.
Analysts forecast that G1 Therapeutics Inc. (GTHX) will achieve an EPS of -$0.83 for the current quarter, -$0.73 for the next quarter and -$4.33 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.99 while analysts give the company a high EPS estimate of -$0.69. Comparatively, EPS for the current quarter was -$0.82 a year ago. Earnings per share for the fiscal year are expected to decrease by -27.60%, and -28.90% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 8 brokerage firm advisors rate G1 Therapeutics Inc. (GTHX) as a “Strong Buy” at a consensus score of 1.60. Specifically, 8 Wall Street analysts polled rate the stock as a buy, while 0 of the 8 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the GTHX, a number of firms have released research notes about the stock. ROTH Capital stated their Buy rating for the stock in a research note on June 26, 2020, with the firm’s price target at $55. H.C. Wainwright coverage for the G1 Therapeutics Inc. (GTHX) stock in a research note released on January 21, 2020 offered a Buy rating with a price target of $82. JP Morgan was of a view on August 08, 2019 that the stock is Overweight, while B. Riley FBR gave the stock Buy rating on February 07, 2019, issuing a price target of $55. JP Morgan on their part issued Neutral rating on January 23, 2019.